Aktienanalyse zu Beyond Air Inc (XAIR)XAIRBeyond Air Inc

Beyond Air, Inc. is a commercial-stage medical device and biopharmaceutical company dedicated to harnessing the power of endogenous and exogenous nitric oxide (NO) to improve the lives of patients suffering from respiratory illnesses, neurological disorders, and solid tumors. Its segments include Beyond Air, Beyond Cancer, and NeuroNos. It has received United States Food and Drug Administration approval for its first system, LungFit PH, for the treatment of term and near-term neonates with hypoxic respiratory failure. The Company is advancing its other LungFit systems in clinical trials for the treatment of severe lung infections such as viral community-acquired pneumonia (including COVID-19) and nontuberculous mycobacteria. It has also partnered with The Hebrew University of Jerusalem to advance a pre-clinical program dedicated to the treatment of autism spectrum disorder and other neurological disorders. Its product pipeline includes LungFit PH, LungFit PRO, LungFit GO, and others. It operates in the Healthcare sector (SURGICAL & MEDICAL INSTRUMENTS & APPARATUS industry).

Beyond Air Inc (XAIR) is a good buy right now due to its current price of $2.1643, which is significantly lower than the analyst price target of $10, indicating a potential upside of over 360%. Additionally, the company has received FDA Breakthrough Device Designation for its LungFit GO device, which could drive future revenue growth. However, the main risk is its high debt-to-equity ratio of 788.94%, indicating potential financial instability.